Plasma oxalate and eGFR are correlated in primary hyperoxaluria patients with maintained kidney function-data from three placebo-controlled studies.
Chronic kidney disease
Clinical trials
Correlation
Plasma oxalate
Primary hyperoxaluria
eGFR
Journal
Pediatric nephrology (Berlin, Germany)
ISSN: 1432-198X
Titre abrégé: Pediatr Nephrol
Pays: Germany
ID NLM: 8708728
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
24
07
2020
accepted:
03
12
2020
revised:
06
11
2020
pubmed:
31
1
2021
medline:
9
2
2022
entrez:
30
1
2021
Statut:
ppublish
Résumé
In patients with primary hyperoxaluria (PH), endogenous oxalate overproduction increases urinary oxalate excretion, leading to compromised kidney function and often kidney failure. Highly elevated plasma oxalate (Pox) is associated with systemic oxalate deposition in patients with PH and severe chronic kidney disease (CKD). The relationship between Pox and estimated glomerular filtration rate (eGFR) in patients with preserved kidney function, however, is not well established. Our analysis aimed to investigate a potential correlation between these parameters in PH patients from three randomized, placebo-controlled trials (studies OC3-DB-01, OC3-DB-02, and OC5-DB-01). Baseline data from patients with a PH diagnosis (type 1, 2, or 3) and eGFR > 40 mL/min/1.73 m A total of 106 patients were analyzed. A statistically significant inverse Spearman's correlation between eGFR and Pox was observed across all analyses; correlation coefficients were - 0.44 in study OC3-DB-01, - 0.55 in study OC3-DB-02, - 0.51 in study OC5-DB-01, and - 0.49 in the pooled studies (p < 0.0064). Baseline evaluations showed a moderate and statistically significant inverse correlation between eGFR and Pox in patients with PH already at early stages of CKD (stages 1-3b), demonstrating that a correlation is present before substantial loss in kidney function occurs.
Sections du résumé
BACKGROUND
In patients with primary hyperoxaluria (PH), endogenous oxalate overproduction increases urinary oxalate excretion, leading to compromised kidney function and often kidney failure. Highly elevated plasma oxalate (Pox) is associated with systemic oxalate deposition in patients with PH and severe chronic kidney disease (CKD). The relationship between Pox and estimated glomerular filtration rate (eGFR) in patients with preserved kidney function, however, is not well established. Our analysis aimed to investigate a potential correlation between these parameters in PH patients from three randomized, placebo-controlled trials (studies OC3-DB-01, OC3-DB-02, and OC5-DB-01).
METHODS
Baseline data from patients with a PH diagnosis (type 1, 2, or 3) and eGFR > 40 mL/min/1.73 m
RESULTS
A total of 106 patients were analyzed. A statistically significant inverse Spearman's correlation between eGFR and Pox was observed across all analyses; correlation coefficients were - 0.44 in study OC3-DB-01, - 0.55 in study OC3-DB-02, - 0.51 in study OC5-DB-01, and - 0.49 in the pooled studies (p < 0.0064).
CONCLUSIONS
Baseline evaluations showed a moderate and statistically significant inverse correlation between eGFR and Pox in patients with PH already at early stages of CKD (stages 1-3b), demonstrating that a correlation is present before substantial loss in kidney function occurs.
Identifiants
pubmed: 33515281
doi: 10.1007/s00467-020-04894-9
pii: 10.1007/s00467-020-04894-9
pmc: PMC8172484
doi:
Substances chimiques
Oxalates
0
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1785-1793Références
Cochat P, Rumsby G (2013) Primary hyperoxaluria. N Engl J Med 369:649–658. https://doi.org/10.1056/NEJMra1301564
doi: 10.1056/NEJMra1301564
pubmed: 23944302
Hoppe B (2012) An update on primary hyperoxaluria. Nat Rev Nephrol 8:467–475. https://doi.org/10.1038/nrneph.2012.113
doi: 10.1038/nrneph.2012.113
pubmed: 22688746
Harambat J, Fargue S, Bacchetta J, Acquaviva C, Cochat P (2011) Primary hyperoxaluria. Int J Nephrol 2011:864580. https://doi.org/10.4061/2011/864580
doi: 10.4061/2011/864580
pubmed: 21748001
pmcid: 3124893
Fargue A, Milliner DS, Knight J, Olson JB, Lowther WT, Holmes RP (2018) Hydroxyproline metabolism and oxalate synthesis in primary hyperoxaluria. J Am Soc Nephrol 29:1615–1623. https://doi.org/10.1681/ASN.2017040390
doi: 10.1681/ASN.2017040390
pubmed: 29588429
pmcid: 6054332
Brzica H, Breljak D, Burckhardt BC, Burckhardt G, Sabolic I (2013) Oxalate: from the environment to kidney stones. Arh Hig Rada Toksikol 64:609–630. https://doi.org/10.2478/10004-1254-64-2013-2428
Lorenz EC, Michet CJ, Milliner DS, Lieske JC (2013) Update on oxalate crystal disease. Curr Rheumatol Rep 15:340. https://doi.org/10.1007/s11926-013-0340-4
doi: 10.1007/s11926-013-0340-4
pubmed: 23666469
pmcid: 3710657
Worcester E, Evan A, Coe F, Lingeman JE, Krambeck A, Sommers A, Philips CL, Milliner D (2013) A test of the hypothesis that oxalate secretion produces proximal tubule crystallization in primary hyperoxaluria type 1. Am J Physiol Renal Physiol 305:F1574–F1584. https://doi.org/10.1152/ajprenal.00382.2013
doi: 10.1152/ajprenal.00382.2013
pubmed: 24089413
pmcid: 3882369
Ermer T, Eckardt KU, Aronson PS, Knauf F (2016) Oxalate, inflammasome, and progression of kidney disease. Curr Opin Nephrol Hypertens 25:363–371. https://doi.org/10.1097/MNH.0000000000000229
doi: 10.1097/MNH.0000000000000229
pubmed: 27191349
pmcid: 4891250
Beck BB, Hoyer-Kuhn H, Göbel H, Habbig S, Hoppe B (2013) Hyperoxaluria and systemic oxalosis: an update on current therapy and future directions. Expert Opin Investig Drugs 22:117–129. https://doi.org/10.1517/13543784.2013.741587
doi: 10.1517/13543784.2013.741587
pubmed: 23167815
Milliner DS, McGregor TL, Thompson A, Dehmel B, Knight J, Rosskamp R, Blank M, Yang S, Fargue S, Rumsby G, Groothoff J, Allain M, West M, Hollander K, Lowther WT, Lieske JC (2020) Endpoints for clinical trials in primary hyperoxaluria. Clin J Am Soc Nephrol. https://doi.org/10.2215/CJN.13821119
Hopp K, Cogal AG, Bergstralh EJ, Barbara SM, Olson JB, Meek AM, Lieske JC, Milliner DS, Harris PC (2015) Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria. J Am Soc Nephrol 26:2559–2570. https://doi.org/10.1681/ASN.2014070698
doi: 10.1681/ASN.2014070698
pubmed: 4587693
pmcid: 4587693
Lieske JC, Monico CG, Holmes WS, Bergstralh EJ, Slezak JM, Roglinger AL, Olson JB, Milliner DS (2005) International registry for primary hyperoxaluria. Am J Nephrol 25:290–296. https://doi.org/10.1159/000086360
doi: 10.1159/000086360
pubmed: 15961949
Shah RJ, Vaughan LE, Enders FT, Milliner DS, Lieske JC (2020) Plasma oxalate as a predictor of kidney function decline in a primary hyperoxaluria cohort. Int J Mol Sci 21:E3608. https://doi.org/10.3390/ijms21103608
doi: 10.3390/ijms21103608
pubmed: 32443777
Perinpam M, Enders FT, Mara KC, Vaughan LE, Ramila AM, Voskoboev N, Milliner DS, Lieske JC (2017) Plasma oxalate in relation to eGFR in subjects with primary hyperoxaluria, enteric hyperoxaluria and urinary stone disease. Clin Biochem 50:1014–1019. https://doi.org/10.1016/j.clinbiochem.2017.07.017
doi: 10.1016/j.clinbiochem.2017.07.017
pubmed: 28764885
pmcid: 5705406
Hillebrand P, Hoppe B (2020) Plasma oxalate levels in primary hyperoxaluria type I show significant intra-individual variation and do not correlate with kidney function. Pediatr Nephrol 35:1227–1233. https://doi.org/10.1007/s00467-020-04531-5
doi: 10.1007/s00467-020-04531-5
pubmed: 32274573
Hoppe B, Groothoff JW, Hulton SA, Cochat P, Niaudet P, Kemper MJ, Deschênes G, Unwin R, Milliner D (2011) Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria. Nephrol Dial Transplant 26:3609–3615. https://doi.org/10.1093/ndt/gfr107
doi: 10.1093/ndt/gfr107
pubmed: 21460356
Milliner D, Hoppe B, Groothoff J (2018) A randomised phase II/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria. Urolithiasis 46:313–323. https://doi.org/10.1007/s00240-017-0998-6
doi: 10.1007/s00240-017-0998-6
pubmed: 28718073
Hoppe B, Niaudet P, Salomon R, Harambat J, Hulton SA, Hoff WV, Moochhala SH, Dechênes G, Lindner E, Sjögren A, Cochat P (2017) A randomised phase I/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria. Pediatr Nephrol 32:781–790. https://doi.org/10.1007/s00467-016-3553-8
doi: 10.1007/s00467-016-3553-8
pubmed: 27924398
Dawson KA, Allison MJ, Hartman PA (1980) Isolation and some characteristics of anaerobic oxalate degrading bacteria from the rumen. Appl Environ Microbiol 40:833–839
doi: 10.1128/AEM.40.4.833-839.1980
Allison MJ, Dawson KA, Mayberry WR, Foss JG (1985) Oxalobacter formigenes gen. Nov., sp. nov.: oxalate-degrading anaerobes that inhabit the gastrointestinal tract. Arch Microbiol 141:1–7. https://doi.org/10.1007/BF00446731
doi: 10.1007/BF00446731
pubmed: 3994481
Kelly JP, Curhan GC, Cave DR, Anderson TE, Kaufman DW (2011) Factors related to colonization with Oxalobacter formigenes in U.S. adults. J Endourol 25:673–679. https://doi.org/10.1089/end.2010.0462
doi: 10.1089/end.2010.0462
pubmed: 21381959
pmcid: 3071521
Knauf F, Lo N, Jiang Z, Robertson WG, Van Itallie CM, Anderson JM, Aronson PS (2011) Net intestinal transport of oxalate reflects passive absorption and SLC26A6-mediated secretion. J Am Soc Nephrol 22:2247–2255. https://doi.org/10.1681/ASN.2011040433
Hatch M, Freel RW (2013) A human strain of Oxalobacter (HC-1) promotes enteric oxalate secretion in the small intestine of mice and reduces urinary oxalate excretion. Urolithiasis 41:379–384. https://doi.org/10.1007/s00240-013-0601-8
doi: 10.1007/s00240-013-0601-8
pubmed: 23959075
Schwartz GJ, Muñoz A, Schneider MF, Robert MH, Frederick K, Bradley WA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629–637. https://doi.org/10.1681/ASN.2008030287
doi: 10.1681/ASN.2008030287
pubmed: 19158356
pmcid: 2653687
Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F (2007) Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 53:766–772. https://doi.org/10.1373/clinchem.2006.077180
Hoppe B, Kemper MJ, Hvizd MG, Sailer DE, Langman CB (1998) Simultaneous determination of oxalate, citrate and sulfate in children’s plasma with ion chromatography. Kidney Int 53:1348–1352. https://doi.org/10.1046/j.1523-1755.1998.00891.x
doi: 10.1046/j.1523-1755.1998.00891.x
pubmed: 9573551
Ladwig PM, Liedtke RR, Larson TS, Lieske JC (2005) Sensitive spectrophotometric assay for plasma oxalate. Clin Chem 51:2377–2380. https://doi.org/10.1373/clinchem.2005.054353
doi: 10.1373/clinchem.2005.054353
pubmed: 16306102
Wolthers BG, Hayer M (1982) The determination of oxalic acid in plasma and urine by means of capillary gas chromatography. Clin Chim Acta 120:87–102. https://doi.org/10.1016/0009-8981(82)90080-8
doi: 10.1016/0009-8981(82)90080-8
pubmed: 7067141
Chen PY, Popovich PM (2002) Correlation: parametric and nonparametric measures. Sage Publications, Thousand Oaks
doi: 10.4135/9781412983808
Cleveland WS, Grosse E (1991) Computational methods for local regression. Stat Comput 1:47–62
doi: 10.1007/BF01890836
da Silva SL, Cochat P, Rech DL, Parant F, de Souza VC, Dubourg L (2018) Association between glomerular filtration rate (measured by high-performance liquid chromatography with iohexol) and plasma oxalate. J Bras Nefrol 40:73–76. https://doi.org/10.1590/1678-4685-JBN-3743
doi: 10.1590/1678-4685-JBN-3743
Rumsby G, Hulton SA (2019) From pathogenesis to novel therapies in primary hyperoxaluria. Expert Opinion on Orphan Drugs 7:57–66. https://doi.org/10.1080/21678707.2019.1571905
doi: 10.1080/21678707.2019.1571905
Stokes F, Acquaviva-Bourdain C, Hoppe B, Lieske JC, Lindner E, Toulson G, Frédéric M, Rumsby G (2020) Plasma oxalate: comparison of methodologies. Urolithiasis. https://doi.org/10.1007/s00240-020-01197-4
Harambat J, Fargue S, Acquaviva C, Gagnadoux MF, Janssen F, Liutkus A, Mourani C, Macher MA, Abramowicz D, Legendre C, Durrbach A, Tsimaratos M, Nivet H, Girardin E, Schott AM, Rolland MO, Cochat P (2010) Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome. Kidney Int 77:443–449. https://doi.org/10.1038/ki.2009.435
doi: 10.1038/ki.2009.435
pubmed: 20016466
Mandrile G, van Woerden CS, Berchialla P, Bodo B, Acquaviva-Bourdain C, Hulton SA, Rumsby G, OxalEurope Consortium (2014) Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type. Kidney Int 86:1197–1204. https://doi.org/10.1038/ki.2014.222
doi: 10.1038/ki.2014.222
pubmed: 24988064